医学
转移性尿路上皮癌
高磷血症
内科学
肿瘤科
疾病
化疗
便秘
癌症
癌
膀胱癌
尿路上皮癌
肾脏疾病
作者
Sumanta K. Pal,Jonathan E. Rosenberg,Jean Hoffman‐Censits,Raanan Berger,David I. Quinn,Matthew D. Galsky,Juergen Wolf,Christian Dittrich,Bhumsuk Keam,Jean‐Pierre Delord,Jan H.M. Schellens,Gwénaëlle Gravis,Jacques Médioni,Pablo Maroto,Virote Sriuranpong,Chaiyut Charoentum,Howard A. Burris,Viktor Grünwald,Daniel P. Petrylak,Ulka N. Vaishampayan
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2018-05-30
卷期号:8 (7): 812-821
被引量:238
标识
DOI:10.1158/2159-8290.cd-18-0229
摘要
Abstract BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. Significance: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status. Cancer Discov; 8(7); 812–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 781
科研通智能强力驱动
Strongly Powered by AbleSci AI